Abstract
Objectives
The study has been commenced to discover the potential of Phlorizin (dual SGLT inhibitor) in streptozotocin induced dementia of Alzheimer’s disease (AD) type.
Material and methods
Injection of Streptozotocin (STZ) was given via i.c.v. route (3 mg/kg) to induce dementia of Alzheimer’s type. In these animals learning and memory was evaluated using Morris water maze (MWM) test. Glutathione (GSH) and thiobarbituric acid reactive species (TBARS) level was quantified to evaluate the oxidative stress; cholinergic activity of brain was estimated in term of acetylcholinesterase (AChE) activity; and the levels of myeloperoxidase (MPO) were measured as inflammation marker.
Results
The mice model had decreased performance in MWM, representing impairment of cognitive functions. Biochemical evaluation showed rise in TBARS level, MPO and AChE activity, and fall in GSH level. The histopathological study revealed severe infiltration of neutrophils. In the study, Phlorizin/Donepezil (serving as positive control) treatment mitigate streptozotocin induced cognitive decline, histopathological changes and biochemical alterations.
Conclusions
The results suggest that Phlorizin decreased cognitive function via its anticholinesterase, antioxidative, antiinflammatory effects and probably through SGLT inhibitory action. It can be conferred that SGLTs can be an encouraging target for the treatment of dementia of AD.
Acknowledgments
The authors are highly thankful to Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala and Chitkara University, Punjab for providing the necessary facilities for conducting the research work. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Not applicable.
-
Ethical approval: The animal protocol was approved by IAEC (Institutional Animal Ethics Committee).
References
1. Stephan, B, Matthews, FE, Ma, B, Muniz, G, Hunter, S, Davis, D, et al.. Alzheimer and vascular neuropathological changes associated with different cognitive states in a non-demented sample. J Alzheim Dis 2012;29:309–18. https://doi.org/10.3233/jad-2011-110518.Search in Google Scholar PubMed PubMed Central
2. Depypere, H, Vierin, A, Weyers, S, Sieben, AN. Alzheimer’s disease, apolipoprotein E and hormone replacement therapy. Maturitas 2016;94:98–105. https://doi.org/10.1016/j.maturitas.2016.09.009.Search in Google Scholar PubMed
3. Fiest, KM, Roberts, JI, Maxwell, CJ, Hogan, DB, Smith, EE, Frolkis, A, et al.. The prevalence and incidence of dementia due to Alzheimer’s disease: a systematic review and meta-analysis. Can J Neurol Sci 2016;43:51–82. https://doi.org/10.1017/cjn.2016.36.Search in Google Scholar PubMed
4. Cass, SP. Alzheimer’s disease and exercise: a literature review. Curr Sports Med Rep 2017;16:19–22. https://doi.org/10.1249/jsr.0000000000000332.Search in Google Scholar
5. Qiu, C, De Ronchi, D, Fratiglioni, L. The epidemiology of the dementias: an update. Curr Opin Psychiatr 2007;20:380–5. https://doi.org/10.1097/yco.0b013e32816ebc7b.Search in Google Scholar
6. WHO Report. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia.Search in Google Scholar
7. Jia, S, Lu, Z, Gao, Z, An, J, Wu, X, Li, X, et al.. Chitosan oligosaccharides alleviate cognitive deficits in an amyloid-β 1–42-induced rat model of Alzheimer’s disease. Int J Biol Macromol 2016;83:416–25. https://doi.org/10.1016/j.ijbiomac.2015.11.011.Search in Google Scholar PubMed
8. Kumar, A, Singh, N. Calcineurin inhibition and protein kinase A activation limits cognitive dysfunction and histopathological damage in a model of dementia of the Alzheimer’s type. Curr Neurovascular Res 2018;15:234–45. https://doi.org/10.2174/1567202615666180813125125.Search in Google Scholar PubMed
9. Mathias, JL, Burke, J. Cognitive functioning in Alzheimer’s and vascular dementia: A meta-analysis; 2009. p. 411.10.1037/a0015384Search in Google Scholar PubMed
10. World Alzheimer Report. 2019. Available from: https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf.Search in Google Scholar
11. Fang, L, Gou, S, Fang, X, Cheng, L, Fleck, C. Current progresses of novel natural products and their derivatives/analogs as anti-Alzheimer candidates: an update. Mini Rev Med Chem 2013;13:870–87. https://doi.org/10.2174/1389557511313060009.Search in Google Scholar PubMed
12. Perry, G, Nunomura, A, Raina, AK, Aliev, G, Siedlak, SL, Harris, PL, et al.. A metabolic basis for Alzheimer disease. Neurochem Res 2003;28:1549–52. https://doi.org/10.1023/a:1025678510480.10.1023/A:1025678510480Search in Google Scholar
13. Iqbal, K, Alonso, AD, Chen, S, Chohan, MO, El-Akkad, E, Gong, CX, et al.. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta (BBA) - Mol Basis Dis 2005;1739:198–210. https://doi.org/10.1016/j.bbadis.2004.09.008.Search in Google Scholar PubMed
14. Mosconi, L, Pupi, A, De Leon, MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci 2008;1147:180–95. https://doi.org/10.1196/annals.1427.007.Search in Google Scholar PubMed PubMed Central
15. Gamba, P, Staurenghi, E, Testa, G, Giannelli, S, Sottero, B, Leonarduzzi, G. A crosstalk between brain cholesterol oxidation and glucose metabolism in Alzheimer’s disease. Front Neurosci 2019;13:556.31.10.3389/fnins.2019.00556Search in Google Scholar PubMed PubMed Central
16. Yaffe, K, Lindquist, K, Schwartz, AV, Vitartas, C, Vittinghoff, E, Satterfield, S, et al.. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 2011;77:1351–6. https://doi.org/10.1212/wnl.0b013e3182315a56.Search in Google Scholar PubMed PubMed Central
17. Xiang, L, Sun, K, Lu, J, Weng, Y, Taoka, A, Sakagami, Y, et al.. Anti-aging effects of phloridzin, an apple polyphenol, on yeast via the SOD and Sir2 genes. Biosci Biotechnol Biochem 2011;75:854–8. https://doi.org/10.1271/bbb.100774.Search in Google Scholar PubMed
18. Ehrenkranz, JR, Lewis, NG, Ronald Kahn, C, Roth, J. Phlorizin: a review. Diabetes Metabol Res Rev 2005;21:31–8. https://doi.org/10.1002/dmrr.532.Search in Google Scholar PubMed
19. Gosch, C, Halbwirth, H, Stich, K. Phloridzin: biosynthesis, distribution and physiological relevance in plants. Phytochemistry 2010;71:838–43. https://doi.org/10.1016/j.phytochem.2010.03.003.Search in Google Scholar PubMed
20. Rizvi, S, Shakil, S, Biswas, D, Shakil, S, Shaikh, S, Bagga, P, et al.. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease-diabetes type 2 linkage via an enzoinformatics study. CNS Neurol Disord - Drug Targets 2014;13:447–51. https://doi.org/10.2174/18715273113126660160.Search in Google Scholar PubMed
21. Yamazaki, Y, Harada, S, Tokuyama, S. Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter. Brain Res 2012;1489:113–20. https://doi.org/10.1016/j.brainres.2012.10.020.Search in Google Scholar PubMed
22. Harada, S, Yamazaki, Y, Nishioka, H, Tokuyama, S. Neuroprotective effect through the cerebral sodium–glucose transporter on the development of ischemic damage in global ischemia. Brain Res 2013;1541:61–8. https://doi.org/10.1016/j.brainres.2013.09.041.Search in Google Scholar PubMed
23. Hutchinson, A, Taper, CD, Towers, GH. Studies of phloridzin in Malus. Can J Biochem Physiol 1959;37:901–10. https://doi.org/10.1139/o59-098.Search in Google Scholar
24. Romberg, C, Mattson, MP, Mughal, MR, Bussey, TJ, Saksida, LM. Impaired attention in the 3xTgAD mouse model of Alzheimer’s disease: rescue by donepezil (Aricept). J Neurosci 2011;31:3500–7. https://doi.org/10.1523/jneurosci.5242-10.2011.Search in Google Scholar
25. Kumar, A, Singh, N. Pharmacological activation of protein kinase A improves memory loss and neuropathological changes in a mouse model of dementia of Alzheimer’s type. Behav Pharmacol 2017;28:187–98.https://doi.org/10.1097/fbp.0000000000000294.Search in Google Scholar
26. Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47–60. https://doi.org/10.1016/0165-0270(84)90007-4.Search in Google Scholar
27. Kumar, A, Singh, N. Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia. Pharmacol Biochem Behav 2017;153:147–59. https://doi.org/10.1016/j.pbb.2016.12.018.Search in Google Scholar
28. Wang, R, Tu, J, Zhang, Q, Zhang, X, Zhu, Y, Ma, W, et al.. Genistein attenuates ischemic oxidative damage and behavioral deficits via eNOS/Nrf2/HO‐1 signaling. Hippocampus 2013;23:634–47. https://doi.org/10.1002/hipo.22126.Search in Google Scholar
29. Ellman, GL, Courtney, KD, Andres, VJr., Feathstone, RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95. https://doi.org/10.1016/0006-2952(61)90145-9.Search in Google Scholar
30. Ohkawa, H, Ohishi, N, Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–8. https://doi.org/10.1016/0003-2697(79)90738-3.Search in Google Scholar
31. Grisham, MB, Benoit, JN, Granger, DN. Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol 1990;186:729–42. https://doi.org/10.1016/0076-6879(90)86172-r.Search in Google Scholar
32. Beutler, E. Improved method for determination of blood glutathione. J Lab Clin Med 1963;61:882–8.Search in Google Scholar
33. Lowry, OH. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75. https://doi.org/10.1016/s0021-9258(19)52451-6.Search in Google Scholar
34. Banchroft, JD, Stevens, A, Turner, DR. Theory and practice of histological technique, 4th ed. New York, London, San Francisco, Tokyo: Churchill Livingstone; 1996.Search in Google Scholar
35. Hooge, R, Deyn, PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 2001;36:60–90.10.1016/S0165-0173(01)00067-4Search in Google Scholar
36. Zhiyou, C. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease (review). Mol Med Rep 2014:1533–41.10.3892/mmr.2014.2040Search in Google Scholar
37. Foy, MR, Baudry, M, Diaz Brinton, R, Thompson, RF. Estrogen and hippocampal plasticity in rodent models. J Alzheimers Dis 2008;15:589–603https://doi.org/10.3233/jad-2008-15406.Search in Google Scholar
38. Singh, M, Sumien, N, Kyser, C, Simpkins, JW. Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci 2008;13:1083–9. https://doi.org/10.2741/2746.Search in Google Scholar
39. Sodhi, RK, Singh, N. All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer’s type. Prog Neuro Psychopharmacol Biol Psychiatr 2013;40:38–46. https://doi.org/10.1016/j.pnpbp.2012.09.012.Search in Google Scholar
40. Packard, MG, Teather, LA, Bazan, NG. Effects of intrastriatal injections of platelet-activating factor and the PAF antagonist BN 52021 on memory. Neurobiol Learn Mem 1996;66:176–82. https://doi.org/10.1006/nlme.1996.0058.Search in Google Scholar
41. Kumar, A, Singh, N. Inhibitor of phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer’s type. Biomed Pharmacother 2017;88:698–707. https://doi.org/10.1016/j.biopha.2017.01.059.Search in Google Scholar
42. Singh, B, Sharma, B, Jaggi, AS, Singh, N. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property. J Renin-Angiotensin-Aldosterone Syst JRAAS 2013;14:124–36. https://doi.org/10.1177/1470320312459977.Search in Google Scholar
43. Li, D, Huang, Y, Cheng, B, Su, J, Zhou, WX, Zhang, YX. Streptozotocin induces mild cognitive impairment at appropriate doses in mice as determined by long-term potentiation and the Morris water maze. J Alzheimers Dis 2016;54:89–98. https://doi.org/10.3233/jad-150979.Search in Google Scholar
44. Plaschke, K, Hoyer, S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int J Dev Neurosci 1993;11:477–83. https://doi.org/10.1016/0736-5748(93)90021-5.Search in Google Scholar
45. Grieb, P. Intracerebroventricular streptozotocin injections as a model of Alzheimer’s disease: in search of a relevant mechanism. Mol Neurobiol 2016;53:1741–52. https://doi.org/10.1007/s12035-015-9132-3.Search in Google Scholar
46. Hoyer, S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late onset sporadic Alzheimers disease. A mini review. J Neural Transm 2002;109:991–1002. https://doi.org/10.1007/s007020200082.Search in Google Scholar
47. Salkovic-Petrisic, M, Hoyer, S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm 2007:217–33. https://doi.org/10.1007/978-3-211-73574-9_28.Search in Google Scholar
48. Cunnane, S, Nugent, S, Roy, M, Courchesne-Loyer, A, Croteau, E, Tremblay, S, et al.. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 2011;27:3–20. https://doi.org/10.1016/j.nut.2010.07.021.Search in Google Scholar
49. Shah, K, DeSilva, S, Abbruscato, T. The role of glucose transporters in brain disease: diabetes and Alzheimer’s disease. Int J Mol Sci 2012;13:12629–55. https://doi.org/10.3390/ijms131012629.Search in Google Scholar
50. Wright, E, Loo, DD, Hirayama, BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733–94. https://doi.org/10.1152/physrev.00055.2009.Search in Google Scholar
51. Oliveira, TL, Candeia-Medeiros, N, Cavalcante-Araújo, PM, Melo, IS, Fávaro-Pípi, E, Fátima, LA, et al.. SGLT1 activity in lung alveolar cells of diabetic rats modulates airway surface liquid glucose concentration and bacterial proliferation. Sci Rep 2016;6:21752. https://doi.org/10.1038/srep21752.Search in Google Scholar
52. Wright, EM, Turk, E. The sodium/glucose cotransport family SLC5. Pflügers Archiv 2004;447:510–18. https://doi.org/10.1007/s00424-003-1202-0.Search in Google Scholar
53. Pellegrini-Giampietro, DE, Gorter, JA, Bennett, MV, Zukin, RS. The GluR2 (GluR-B) hypothesis: Ca2+-permeable AMPA receptors in neurological disorders. Trends Neurosci 1997;20:464–70. https://doi.org/10.1016/s0166-2236(97)01100-4.Search in Google Scholar
54. Yoshiyama, Y, Kojima, A, Ishikawa, C, Arai, K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheim Dis 2010;22:295–306. https://doi.org/10.3233/jad-2010-100681.Search in Google Scholar
55. Dhingra, D, Kumar, V. Memory-enhancing activity of palmatine in mice using elevated plus maze and Morris water maze. Adv Pharmacol Sci 2012:1–7. https://doi.org/10.1155/2012/357368.Search in Google Scholar PubMed PubMed Central
56. Bhullar, KS, Rupasinghe, HP. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev 2013:1–18. https://doi.org/10.1155/2013/891748.Search in Google Scholar PubMed PubMed Central
57. Umukoro, S, Adewole, FA, Eduviere, AT, Aderibigbe, AO, Onwuchekwa, C. Free radical scavenging effect of donepezil as the possible contribution to its memory enhancing activity in mice. Drug Res 2014;64:236–9.10.1055/s-0033-1357126Search in Google Scholar PubMed
58. Cutuli, D, De Bartolo, P, Caporali, P, Tartaglione, AM, Oddi, D, D’Amato, FR, et al.. Neuroprotective effects of donepezil against cholinergic depletion. Alzheimer’s Res Ther 2013;5:50. https://doi.org/10.1186/alzrt215.Search in Google Scholar PubMed PubMed Central
59. Dong, H, Yuede, CM, Coughlan, CA, Murphy, KM, Csernansky, JG. Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer’s disease. Brain Res 2009;1303:169–78. https://doi.org/10.1016/j.brainres.2009.09.097.Search in Google Scholar PubMed PubMed Central
60. Meguro, K, Ouchi, Y, Akanuma, K, Meguro, M, Kasai, M. Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer’s patients in long-term care health facilities. BMC Neurol 2014;14:243. https://doi.org/10.1186/s12883-014-0243-7.Search in Google Scholar PubMed PubMed Central
© 2021 Walter de Gruyter GmbH, Berlin/Boston
